Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Thyroid Cancer

Thyroid Cancer

76

Pipeline Programs↗

106

Active Trials↗

46

Companies Involved↗

Thyroid Cancer is a moderately active landscape with 76 programs across 46 companies. The most active players are Eli Lilly, AffyImmune Therapeutics, Inc., AstraZeneca. 12 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

73/100

Pipeline Velocity

52/100

Mech. Concentration

9/100

Completion Rate

78/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Eli Lilly

1 program

AffyImmune Therapeutics, Inc.

1 program

AstraZeneca

1 program

Pipeline

Programs by Phase

Preclinical25

Levothyroxine Sodium

Institut Jerome Lejeune

Ferumoxytol

Azurity Pharmaceuticals

Carbon Nanoparticles

Peking University Cancer Hospital & Institute

Levothyroxin

Berlin-Chemie AG Menarini Group

RET Inhibitor

Fudan University

Phase 18

Durvalumab

AstraZeneca

Lapatinib Ditosylate

Novartis

Lapatinib

GSK

AIC100 CAR T Cells

AffyImmune Therapeutics, Inc.

Hyperpolarized 13-C-Pyruvate

M.D. Anderson Cancer Center

Phase 231

Nivolumab

Bristol-Myers Squibb

Thyrogen

Genzyme, a Sanofi Company

Sorafenib With Everolimus

Memorial Sloan Kettering Cancer Center

Levothyroxine

Institut Jerome Lejeune

Surufatinib

Hutchison Medipharma Limited

Phase 312

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Mitoxantrone Hydrochloride

Pfizer

Metformin

EMD Serono

Trametinib

Novartis

Approved

No programs

Analysis

Modality Breakdown

85%

Small molecule

63 of 74 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 74 classified programs, each share of the total. Modality classified for 97% of 76 pipeline programs.

Analysis

Trial Status

319

clinical trials

Completed136 · 43%

Recruiting54 · 17%

Unknown status36 · 11%

Active, not recruiting32 · 10%

Terminated25 · 8%

Not yet recruiting17 · 5%

Other19 · 6%

Clinical Trials

Trial Activity

319 trials

Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.

Recruiting·MM.D. Anderson Cancer Center·N/A·NCT06507878·459 enrolled

A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.

Recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT06235216·42 enrolled

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT04927416·54 enrolled

Multi-center, 1:1 Randomized, Stratified, Parallel-group, Non-inferiority Clinical Trial of Small Thyroid Cancers Treated With Hemithyroidectomy or Radiofrequency Ablation.

Recruiting·UUniversity of Aarhus·Preclinical·NCT06796348·88 enrolled

Establishment of a Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

Recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·Preclinical·NCT04104529·350 enrolled

Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT07218315·15 enrolled

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03647358·75 enrolled

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03841617·30 enrolled

Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer

Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT01109420·500 enrolled

NEO-COMBAT XL: Neoadjuvant and Maintenance XL092 and Cemiplimab in BRAF V600E-wildtype Anaplastic Thyroid Cancer: a Phase 1B Study

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06902376·12 enrolled

Studies on Thyroid Nodules and Thyroid Cancer

Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00001160·2,500 enrolled

Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer: A Randomized, Controlled, Non-inferiority, Phase 2 Study

Recruiting·FFudan University·Phase 2·NCT07777536·72 enrolled

Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy: A Prospective Study.

Recruiting·MMinia University·N/A·NCT07059507·280 enrolled

A Functional-oriented Modification of TOaST Based on Partial Preservation of the Lines Alba Cervical

Recruiting·SShanghai 6th People's Hospital·N/A·NCT06738888·300 enrolled

An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03099356·22 enrolled

Page 1 of 22

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)